Want to see RVTY full AI Analyst Report?
Earnings Data
Report Date
Aug 03, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.21Last Year’s EPS
1.18Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a generally positive tone driven by a better-than-expected Q1 (organic growth, margin and EPS beats), strong cash conversion, healthy software ARR trends, and a strategic decision to divest a underperforming China diagnostics business that should improve longer-term margins and growth. Near-term cautions include China market weakness, Q2 software cadence volatility, a ~$0.15 EPS headwind in 2026 from the divestiture (with proceeds not realized until 2027), and reduced FX tailwinds. Management emphasized operational cost initiatives and expected margin expansion into the second half of the year and into 2027, supporting an upbeat long-term outlook despite the identified near-term risks.Company Guidance
Quarterly Revenue and Organic Growth
Generated total revenue of $711 million in Q1; reported total-company organic growth of 3% in the quarter. On a pro forma basis (excluding China immunodiagnostics), Q1 revenue would have been $687 million and pro forma organic growth would have been 6%.
Adjusted Operating Margin Outperformance
Delivered adjusted operating margin of 23.6% for the quarter, above prior 23% outlook; pro forma adjusted operating margin for the quarter was 24%. Full-year pro forma margin guidance raised to 28.4%.
Earnings Per Share Beat
Adjusted EPS of $1.06 in Q1, beating the implied guidance range of $1.02–$1.04. Pro forma Q1 adjusted EPS would have been $1.04.
Strong Cash Generation and Balance Sheet
Generated free cash flow of $115 million in Q1 with a 97% conversion of adjusted net income. Ended the quarter with net debt to adjusted EBITDA of 2.8x; 100% fixed-rate debt with weighted-average interest rate of 2.6% and ~6 years weighted average maturity.
Strategic Portfolio Action — China Immunodiagnostics Divestiture
Announced intent to divest China immunodiagnostics (≈6% of company revenue last year). Pro forma, this is expected to improve 2026 total-company organic growth by ~100 basis points and enhance operating margins by ~30 basis points, and materially improve cash-flow conversion going forward.
Software and AI Momentum
Signals software and new product launches (Xynthetica, BioDesign, LabGistics) highlighted. SaaS/ARR growth remains robust (management cited ~30–40% ARR growth YoY and strong SaaS pipeline); software APV and SaaS metrics growing double digits.
Segment and Product Strengths — Reproductive Health & Instruments
Diagnostics reproductive health grew low double digits organically; newborn screening grew low double digits. Life Sciences instrumentation saw mid-single-digit growth; strong demand for high-content screening products (e.g., Opera Phenix OptIQ) tied to AI-driven research trends.
Capital Return and Share Count
Repurchased $86 million of shares in Q1; diluted average share count ~111.9 million. Management indicated continued opportunistic share buybacks as a capital deployment priority.
RVTY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RVTY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $86.51 | $92.30 | +6.69% |
Feb 02, 2026 | $108.71 | $107.01 | -1.57% |
Oct 27, 2025 | $98.75 | $97.03 | -1.75% |
Apr 28, 2025 | $94.02 | $94.79 | +0.82% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Revvity, Inc. (RVTY) report earnings?
Revvity, Inc. (RVTY) is schdueled to report earning on Aug 03, 2026, After Close (Confirmed).
What is Revvity, Inc. (RVTY) earnings time?
Revvity, Inc. (RVTY) earnings time is at Aug 03, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RVTY EPS forecast?
RVTY EPS forecast for the fiscal quarter 2026 (Q2) is 1.21.
